Bluebird's gene therapy continues to show promise in early study
(Reuters) - Biotech firm Bluebird Bio Inc said its experimental gene therapy continued to exhibit a positive effect in an ongoing early-stage study of patients with rare types of blood disorders.
No comments:
Post a Comment